Semaglutide vs Liraglutide

Semaglutide achieves greater A1C reduction and weight loss than liraglutide. The SUSTAIN 10 trial directly compared semaglutide 1 mg weekly with liraglutide 1.2 mg daily and found semaglutide reduced A1C by 1.7% vs. 1.0% for liraglutide, with significantly greater weight loss (5.8 kg vs. 1.9 kg).

For weight management, the STEP trials showed semaglutide 2.4 mg (Wegovy) achieved approximately 15-17% body weight loss, compared to approximately 8% with liraglutide 3.0 mg (Saxenda) in the SCALE trials.

Both drugs have cardiovascular outcome data. SUSTAIN-6 showed semaglutide reduced MACE by 26%, while the LEADER trial showed liraglutide reduced MACE by 13% and cardiovascular death by 22%. Both are indicated to reduce cardiovascular risk in type 2 diabetes patients with established cardiovascular disease.

Both drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, and decreased appetite. These are most common during dose initiation and generally improve with time.

Nausea rates are comparable between the two drugs. The once-weekly dosing of semaglutide may lead to more sustained GI effects in some patients, while liraglutide's daily dosing allows more gradual dose adjustments.

Both carry the GLP-1 class warnings: thyroid C-cell tumor risk (rodent data), pancreatitis, and contraindication in MTC/MEN 2. Both can cause hypoglycemia when used with insulin or sulfonylureas.

Liraglutide has a longer postmarketing safety record (approved 2010 vs. 2017 for semaglutide) and more extensive real-world safety data.

Both are brand-name medications with no generics currently available. Liraglutide (Victoza) costs approximately $800-$900/month, and semaglutide (Ozempic) costs approximately $900-$1,000/month at list price.

For weight management, Saxenda (liraglutide 3.0 mg) and Wegovy (semaglutide 2.4 mg) are similarly expensive at approximately $1,300-$1,600/month at list price. Insurance coverage for obesity indications varies widely.

Both manufacturers offer savings programs for commercially insured patients. Actual out-of-pocket costs vary significantly based on insurance coverage.

The most significant convenience difference is dosing frequency. Semaglutide is injected once weekly, while liraglutide requires daily injection. For most patients, once-weekly dosing is substantially more convenient and may improve long-term adherence.

Liraglutide requires daily dose titration during initiation (0.6 mg for one week, then 1.2 mg, then optional increase to 1.8 mg). Semaglutide starts at 0.25 mg weekly for 4 weeks, then increases to 0.5 mg, with optional increase to 1 mg.

Both use pen injectors. Semaglutide is a multi-dose pen; liraglutide is also a multi-dose pen. Both require refrigeration before first use.

Semaglutide is also available as a daily oral tablet (Rybelsus), providing a non-injectable option not available with liraglutide for diabetes.

Semaglutide is generally preferred over liraglutide for most patients due to its greater efficacy (A1C and weight reduction), once-weekly dosing convenience, and strong cardiovascular data. It represents the newer generation of GLP-1 therapy.

Liraglutide may still be preferred in situations where daily dose flexibility is beneficial, when insurance formulary placement favors it, or when the longer real-world safety track record provides additional comfort. Some patients may also prefer the more gradual dose titration.

For weight management specifically, semaglutide (Wegovy) produces nearly twice the weight loss of liraglutide (Saxenda). Consult your healthcare provider and check your insurance coverage when choosing between these medications.